Coagulation Factor VIII Inhibitor Screen, Plasma
Use
This test is useful for detecting the presence of a specific factor inhibitor directed against coagulation factor VIII. Factor VIII inhibitors can develop in patients with congenital factor VIII deficiency (hemophilia A) as well as in non-hemophiliac patients, such as the elderly, postpartum patients, and patients with autoimmune disease. Testing includes a coagulation factor VIII activity assay with dilutions to evaluate assay inhibition. If specific inhibition is apparent, it will be titered.
Special Instructions
This test is only orderable as a reflex associated with other evaluations such as Factor VIII Inhibitor Evaluation, Lupus Anticoagulant Profile, Bleeding Diathesis Profile, Prolonged Clot Time Profile, and von Willebrand Disease Profile. Please refer to the Coagulation Guidelines for Specimen Handling and Processing for detailed instructions.
Limitations
Occasionally, a potent lupus-like anticoagulant may cause false-positive results for a specific factor inhibitor, including factor VIII. Interpretation is based on the comparison of the factor VIII activity results with expected values after incubation with normal plasma.
New York Approved
Methodology
Other (Optical Clot-Based)
Biomarkers
LOINC Codes
- 3206-0
- 3206-0
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
Not provided
Minimum Volume
2 mL
Collection Instructions
Refer to the Coagulation Guidelines for Specimen Handling and Processing for detailed instructions.
Causes for Rejection
Gross hemolysis, gross lipemia, gross icterus
Stability Requirements
| Temperature | Period |
|---|---|
| Frozen | 14 days |